Cartalax vs PTD-DBM

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Contains a protein transduction domain enabling intracellular delivery. Disrupts Dishevelled-Axin protein interaction, preventing β-catenin degradation and activating Wnt target genes essential for hair follicle cycling and new follicle neogenesis.

PTD-DBM is a synthetic peptide combining a protein transduction domain (PTD) with a Dishevelled-binding motif (DBM) derived from the CXXC5 protein, engineered to penetrate cells and disrupt the CXXC5-Dishevelled protein-protein interaction that normally suppresses Wnt/beta-catenin signaling, with the goal of reactivating the Wnt pathway in hair follicle stem cells to promote follicle cycling and hair regrowth in androgenetic alopecia. The proposed mechanism targets a specific negative regulatory checkpoint: CXXC5 binds Dishevelled to prevent beta-catenin nuclear translocation; the PTD-DBM peptide competitively disrupts this interaction to restore Wnt pathway activity in follicular dermal papilla cells, a mechanism demonstrated to stimulate hair follicle activation in preclinical mouse models of hair loss. No published human clinical trials, pharmacokinetic studies, or Phase 1 safety data for PTD-DBM have been indexed in PubMed; available indexed literature consists of preclinical cell-based and mouse studies examining the CXXC5/Wnt/DHT signaling axis in androgenetic alopecia, with no human data characterizing this compound's safety, bioavailability, or efficacy. PTD-DBM has no FDA approval or approved indication in any jurisdiction; it is a research compound with a well-defined preclinical mechanistic rationale targeting the Wnt pathway but no published human data, and its development status as a clinical candidate has not been established in the indexed scientific literature.